S32
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital, Private Equity, Hedge Funds, Real Estate, Commodities, Crypto, Fixed Income (Debt and Bonds), Infrastructure, ESG and Impact Investing, Collectibles & Art, Distressed and Special Situations
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO, Buyout, Turnaround, Distressed
Geographical Focus
United States, United Kingdom, Canada, Germany, Hong Kong, Japan, Australia, Singapore, China, India, Brazil, France, United Arab Emirates, Switzerland, Mexico, South Korea, Netherlands, South Africa, Sweden, Israel
Industries Focus
- Healthcare
- Software
- FinTech
- Artificial Intelligence
- Gaming
- Life Sciences
- Cybersecurity
- Quantum Computing
- Machine Learning
- Cloud Computing
- Biotechnology
- Enterprise Software
- Computational Biology
- Data Infrastructure
- Precision Medicine
Investment Size:
1,000,000 to 100,000,000 USD
Investor Details Founded: 2017
S32 is a venture capital firm investing at the frontiers of technology, healthcare, and life sciences. Founded by Bill Maris, the team has deep experience building iconic companies. Their goal is to accelerate the discovery, development, and distribution of revolutionary technologies that improve the human condition. S32 invests across the entirety of technology, including artificial intelligence, enterprise software, cybersecurity, fintech, quantum computing, computational biology, and biotechnology. The firm has over $2 billion under management and has backed over 100 startups across various software-driven industries, including cybersecurity, quantum and precision medicine, and computational biology. Notable investments include Cohere, Inceptive, Deel, Inworld, Gusto, Phaidra, and BigHat Biosciences. In October 2023, S32 closed its Fund 5, an oversubscribed $525 million fund, to invest in companies advancing software and artificial intelligence to enable new capabilities across markets such as enterprise software, cybersecurity, data infrastructure, gaming, fintech, precision medicine, and computational biology. In February 2024, Dr. Andy Conrad, known for his leadership in technology and advanced data science, joined S32 as a General Partner. Dr. Conrad previously founded and served as the CEO and Executive Chairman of Verily Life Sciences at Alphabet (Google).
Requirements
- Focus on software-driven businesses in technology and healthcare sectors
- Investments in companies at various stages, from seed to late stage
- Geographical focus on United States and select international markets
- Interest in industries such as artificial intelligence, enterprise software, cybersecurity, fintech, quantum computing, computational biology, and biotechnology
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Cohere
- Inceptive
- Deel
- Inworld
- Gusto
- Phaidra
- BigHat Biosciences
- Coinbase
- Crowdstrike
- Thrive
- Relay
- Cue
- Auris
- SandboxAQ
- Gretel Labs
Mentioned In
-
$49.95
-
$9.95
-
$14.95
-
$19.95
-
$14.95
-
$39.95
-
$19.95
-
$24.95
-
$19.95
-
$19.95
-
$24.95
-
$99.00
-
$299.00
Claim this Investor
Are you an official representative of S32?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim